海外の治験の状況「1」での検索結果
259件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared with Once-Daily Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus on Oral Agents
- Type II diabetes MedDRA version: 14.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Brazil, Indonesia, Spain, United States
- 2012-03-30
Authorised
- A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.
- Type 1 Diabetes MedDRA version: 20.0 Level: LLT Classification code 10020639 Term: Hyperglycemia System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Argentina, Australia, Austria, Brazil, Germany, Greece, India, Italy, Japan, Mexico, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United States
- 2017-04-03
Authorised
- A Phase 3 clinical study to evaluate the safety and efficacy of the study medication Rociletinib compared to pemetrexed, gemcitabine, docetaxel, or paclitaxel in subjects with Non-Small Cell Lung Cancer
- Patients with EGFR mutant Non-Small Cell Lung Cancer who have failed at least 1 previous EGFR-directed TKI and 1 line of platinum-containing doublet chemotherapy MedDRA version: 19.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, France, Germany, Italy, Korea, Republic of, Netherlands, Spain, Taiwan, United Kingdom, United States
- 2014-12-23
Authorised
- A study to evaluate the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected patients that have not been treated yet.
- Human Immunodeficiency Virus-1 infection MedDRA version: 20.1 Level: LLT Classification code 10068341 Term: HIV-1 infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Romania, Russian Federation, South Africa, Spain, Taiwan, Ukraine, United Kingdom, United States
- 2016-05-20
Authorised
- A study to evaluate the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV- 1-infected patients that have not been treated yet.
- Human Immunodeficiency Virus-1 infection MedDRA version: 20.1 Level: LLT Classification code 10068341 Term: HIV-1 infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, South Africa, Spain, Switzerland, Taiwan, Ukraine, United Kingdom, United States
- 2016-05-25
Authorised
- A Study Comparing SB4 to Enbrel® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy
- Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB4 is Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), plaque Psoriasis (PsO) and paediatric plaque PsO. MedDRA version: 14.1 Level: SOC Classification code 10021428 Term: Immune system disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Bulgaria, Colombia, Czech Republic, Hungary, India, Korea, Republic of, Lithuania, Mexico, Poland, Ukraine, United Kingdom
- 2013-02-20
Authorised
- A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed.
- Human immunodeficiency virus type 1 (HIV-1) MedDRA version: 17.1 Level: LLT Classification code 10003582 Term: Asymptomatic human immunodeficiency virus type I infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, United States
- 2015-04-14
Authorised
- A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed
- Human immunodeficiency virus type 1 (HIV-1) MedDRA version: 17.1 Level: LLT Classification code 10003582 Term: Asymptomatic human immunodeficiency virus type I infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, United States
- 2015-04-14
Authorised
- Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, over a 24-week period.
- Type 2 Diabetes Mellitus MedDRA version: 14.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, India, Ireland, Israel, Italy, Korea, Democratic People's Republic of, Lithuania, Mexico, New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Turkey, United Kingdom, United States
- 2011-10-18
Authorised
- Study Evaluation of the Long Term Safety of Etanercept In 3 Sub-types of Childhood Arthritis
- OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS MedDRA version: 14.0 Level: LLT Classification code 10059176 Term: Juvenile idiopathic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Belgium, Colombia, Czech Republic, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Netherlands, Norway, Poland, Russian Federation, Serbia, Slovakia, Slovenia, Spain
- 2011-06-08
